Developer docs
API playgroundTry for free, no card

Search company profiles

Nmible

Full company profile

uuid000a7im

Namestring
Nmible
Websiteurl
nmible.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Nmible is a privately held, early-stage company headquartered in Harrow, United Kingdom, founded in 2020. Per its public firmographic profile, the company provides clinical trial participant reimbursement solutions to the life sciences industry — addressing the operational workflow of paying and reimbursing participants enrolled in clinical studies, a function typically performed by pharmaceutical sponsors and contract research organizations (CROs). The company is led by Jonathan Anderson, Founder and CEO.

The available source material offers no detail on Nmible's product architecture, underlying technology stack, integration footprint, proprietary features, or competitive differentiation. The firm's website (nmible.com) was observed to display only a loading/verification placeholder rather than substantive product content, and no patents, certifications, partnerships, awards, product launches, or technology disclosures were captured. Consequently, the technical and commercial mechanics of the offering cannot be characterized beyond the stated reimbursement-services value proposition.

On the commercial side, the company operates with a headcount in the 1–10 range and has no disclosed revenue, funding history, pricing model, customer base, or distribution channels in the supplied data. Ownership, subsidiary structure, and operating geographies beyond the Harrow, UK headquarters are likewise not documented. The combination of a niche regulated vertical (clinical trial finance) and minimal public footprint is consistent with either a very early commercial stage or a pre-commercial posture; the source material does not allow further differentiation between these readings.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBirmingham, United Kingdom
HQ citystring
Birmingham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
clinical trial reimbursement, participant payments, life sciences software, trial finance solutions, patient reimbursement
Industry2 codes
PRIMARYHLAGACAM
Clinical Trial Financial Management & Payments (Site Budgeting)
SECONDARYHLAIAKAG
Patient Access Programs & Affordability (Copay/Hubs/PSP)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
NAICS code1 code
  • Professional, Scientific, and Technical Services541
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Participant Reimbursement Software
Social media profiles3 records
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Nmible provides clinical trial participant reimbursement solutions to the life sciences industry. The company enables sponsors and contract research organizations to manage payments to trial participants, though specific product functionality is not detailed in available public sources.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers5 records
1Oracle Health Sciences
TypeBroad incumbent
TypeBroad incumbent
Description

Veeva provides clinical trial and site management software (Veeva Vault Clinical) widely used by sponsors and CROs, representing adjacent infrastructure that touches trial finance and site operations.

TypeBroad incumbent
Description

Medidata (Dassault Systèmes) offers the Medidata Clinical Cloud including financial and site management tools used by sponsors running clinical trials, overlapping with participant reimbursement workflows.

TypeBroad incumbent
Description

IQVIA is a global CRO and clinical trial technology provider with site payment and financial management capabilities, making it a broad incumbent in the same customer workflow that Nmible serves.

TypeDirect peer
Description

Greenphire is the dominant provider of clinical trial participant payment and reimbursement solutions (ClinCard) and is the most direct competitor to Nmible's stated offering.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nmible

Clinical Trial Participant Reimbursement Softwarenmible.com

What Nmible does

Nmible is a privately held, early-stage company headquartered in Harrow, United Kingdom, founded in 2020. Per its public firmographic profile, the company provides clinical trial participant reimbursement solutions to the life sciences industry — addressing the operational workflow of paying and reimbursing participants enrolled in clinical studies, a function typically performed by pharmaceutical sponsors and contract research organizations (CROs). The company is led by Jonathan Anderson, Founder and CEO.

The available source material offers no detail on Nmible's product architecture, underlying technology stack, integration footprint, proprietary features, or competitive differentiation. The firm's website (nmible.com) was observed to display only a loading/verification placeholder rather than substantive product content, and no patents, certifications, partnerships, awards, product launches, or technology disclosures were captured. Consequently, the technical and commercial mechanics of the offering cannot be characterized beyond the stated reimbursement-services value proposition.

On the commercial side, the company operates with a headcount in the 1–10 range and has no disclosed revenue, funding history, pricing model, customer base, or distribution channels in the supplied data. Ownership, subsidiary structure, and operating geographies beyond the Harrow, UK headquarters are likewise not documented. The combination of a niche regulated vertical (clinical trial finance) and minimal public footprint is consistent with either a very early commercial stage or a pre-commercial posture; the source material does not allow further differentiation between these readings.

Nmible firmographics

Firmographics
Name
Nmible
Website
https://nmible.com
Company type
Private
Founded year
2020
Headcount range
11–50 employees
Ownership category
akta.pro rank

Nmible industry classification

Industry
Product category
Clinical Trial Participant Reimbursement Software
NAICS
Professional, Scientific, and Technical Services (541)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGACAM
Clinical Trial Financial Management & Payments (Site Budgeting)
SECONDARYHLAIAKAG
Patient Access Programs & Affordability (Copay/Hubs/PSP)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing

Keywords

  • Clinical trial reimbursement
  • Participant payments
  • Life sciences software
  • Trial finance solutions
  • Patient reimbursement

Where Nmible is headquartered

Location

Headquarters

HQ city
Birmingham
HQ country
United Kingdom
HQ region
Europe

Markets served

Nmible business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Nmible product offering

Product offering

Core offering

Nmible provides clinical trial participant reimbursement solutions to the life sciences industry. The company enables sponsors and contract research organizations to manage payments to trial participants, though specific product functionality is not detailed in available public sources.

Differentiator

Problem solved

Functional benefit

Companies that use Nmible

Customer profile

Ideal customer profiles1 record

Nmible technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Nmible partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Nmible competitors and assessment

Company assessment

Broad incumbents

  • Oracle Health Sciences:
  • Veeva Systems: Veeva provides clinical trial and site management software (Veeva Vault Clinical) widely used by sponsors and CROs, representing adjacent infrastructure that touches trial finance and site operations.
  • Medidata Solutions: Medidata (Dassault Systèmes) offers the Medidata Clinical Cloud including financial and site management tools used by sponsors running clinical trials, overlapping with participant reimbursement workflows.
  • IQVIA: IQVIA is a global CRO and clinical trial technology provider with site payment and financial management capabilities, making it a broad incumbent in the same customer workflow that Nmible serves.

Direct peers

  • Greenphire: Greenphire is the dominant provider of clinical trial participant payment and reimbursement solutions (ClinCard) and is the most direct competitor to Nmible's stated offering.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Nmible social profiles

Digital presence

Nmible financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nmible leadership team

Management profile

Number of profiles

Profiles1 record

Nmible funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nmible M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nmible

What does Nmible do?

Nmible provides clinical trial participant reimbursement solutions to the life sciences industry. The company enables sponsors and contract research organizations to manage payments to trial participants, though specific product functionality is not detailed in available public sources.

When was Nmible founded?

Nmible was founded in 2020. It employs 11 to 50 people.

Where is Nmible based?

Nmible is headquartered in Birmingham, United Kingdom, in the Europe region.

Who are Nmible's main competitors?

Broad incumbents on record are Oracle Health Sciences, Veeva Systems, Medidata Solutions and IQVIA. Greenphire is listed as a direct peer.

Does Nmible have an API?

No public API is recorded for Nmible.

What industry is Nmible in?

Nmible's product category is Clinical Trial Participant Reimbursement Software. Its primary akta.pro industry code is HLAGACAM, Clinical Trial Financial Management & Payments (Site Budgeting), with a secondary code of HLAIAKAG, Patient Access Programs & Affordability (Copay/Hubs/PSP). Its NAICS code is 541 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRyght and nmible partner to streamline participant payment data automation and security for clinical trialsRyght and nmible announced a partnership to integrate Ryght's generative AI into nmible's clinical trial reimbursement platform. The collaboration aims to automate data processing, enhance security, and optimize workflows for trial sponsors and CROs. Ryght Preview is available as a free, secure platform for life sciences knowledge workers.GlobeNewswirenmible partners with Velocity Clinical Research to streamline clinical trials patient stipendsnmible will embed its reimbursement platform into Velocity Clinical Research's patient recruitment app, streamlining patient stipend payments. The partnership is estimated to save Velocity over 650 working days annually and process more than $20 million in payments. nmible plans to scale the solution to other life sciences companies.GlobeNewswirenmible partners with Velocity Clinical Research to streamline clinical trials patient stipendsnmible will embed its reimbursement platform into Velocity Clinical Research's patient recruitment app, streamlining patient stipend payments. The partnership is estimated to save Velocity over 650 working days annually and process more than $20 million in payments. nmible plans to scale the solution to other life sciences companies.Yahoonmible partners with Velocity Clinical Research to streamline clinical trials patient stipendsnmible will embed its reimbursement platform into Velocity Clinical Research's patient recruitment app, streamlining patient stipend payments. The solution is estimated to save Velocity over 650 working days annually and process more than $20 million in payments. The partnership is one of four deals targeting life sciences and CROs.